Integrated Biopharma Inc (INBP) — 10-K Filings
All 10-K filings from Integrated Biopharma Inc. Browse 2 Annual Report reports with AI-powered summaries and risk analysis.
10-K Filings (2)
-
INBP's Revenue Highly Concentrated, Faces Stiff Competition
— Sep 23, 2025 Risk: high
INTEGRATED BIOPHARMA INC (INBP) reported a significant concentration of consolidated net sales, with approximately 84% in fiscal year 2025 and 90% in fiscal yea -
Integrated Biopharma Reports FY24 Results
— Sep 20, 2024 Risk: low
Integrated Biopharma Inc. filed its 10-K for the fiscal year ending June 30, 2024. The company reported total assets of $1,289 million and total liabilities of
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX